This episode is brought to you by Allogene, a company redefining how we fight cancer and autoimmune disease.

By pushing the boundaries of Cartyce cell therapy, Allogene is creating next generation off-the-shelf treatments designed to reach more people.

Learn more at Allogene.com.

Hi, everyone.

Cancer treatment has come such a long way from the blunt tools of chemo to today's precision

immunotherapies like CAR-T or chimeric antigen receptor T-cell therapy.

Our partner, Allogene Therapeutics, is helping lead that transformation.

Carty is amazing. It reprograms your own immune cells to find and destroy cancer. And because it's

targeted, it does it without some of the most brutal side effects of, say, chemotherapy. But access has been a real challenge.

That's where Allogene comes in, developing truly off-the-shelf, card tea treatments, made from

healthy donor cells, and ready when patients need them most. Who better to understand these

exciting developments than Allogene's chief medical officer, Dr. Zach Roberts.

We talked about how cancer outsmart some of its fiercest opponents, but how CAR-T therapy is changing

the face of the disease. But first, I wanted to know what drew him to cancer research in the first

place. Dr. Zachary Roberts, so nice to meet you. I admire people like you so much who are

cancer scientists, who are trying to come up with better treatments to save people's lives

or to at least manage their disease. I'm curious, how did you get interested in

cancer research? And by the way, thank you that I appreciate that you did. Well, thanks, Katie.

This is absolutely lovely to be here with you today. I have to say that I was interested from a very, very

young age. I grew up wanting to be a scientist, wanting to be a doctor.

I became quite fascinated with how cells kind of went wrong. They're a normal cell one day,

and then they're a cancer cell the next. And so really understanding what genes were in play,

...